If lecanemab (Leqembi), an antibody infusion for early Alzheimer's disease that clears brain amyloid, is not helping, the next step is a prompt medical review to decide whether to stop it. Care then shifts to symptom treatment, daily support, safety planning, and possible clinical trial options. Continued decline does not always mean the drug failed, because decline continued even in the successful trial. As reported by CMAJ, both groups worsened over 18 months and lecanemab slowed decline by 0.45 points on an 18-point scale Clarity AD trial summary.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How can you tell it is not helping?
- When do side effects mean stopping?
- Can you switch to donanemab instead?
- What care helps after lecanemab stops?
How can you tell it is not helping?
Memory, thinking, or daily function may keep slipping despite regular infusions. Small changes are hard to judge at home, so ask the prescribing team to compare cognition tests, function, and brain scans over time. The treatment goal is slower decline, not improvement or a cure.
CMAJ notes the trial difference did not reach the roughly 1-point change patients would notice, so expectations should stay narrow. Lack of clear benefit is itself a reason to reassess. As described in a U.S. real-world report from Eisai, some patients stopped treatment, and ongoing decline should trigger a direct talk about risks, burden, and whether to continue.
When do side effects mean stopping?
Lecanemab carries an FDA boxed warning for amyloid-related imaging abnormalities, with brain swelling called ARIA-E and bleeding called ARIA-H. Warning signs include headache, confusion, dizziness, vision change, nausea, or unusual bleeding symptoms. Monitoring uses brain MRI scans before treatment and during treatment.
As reported by American Pharmaceutical Review describing the FDA recommendation, an earlier MRI before the 3rd infusion was recommended in August 2025, in addition to MRIs before the 5th, 7th and 14th infusions FDA monitoring update. Risk is higher with the APOE4 gene, especially with two copies, so CMAJ reports APOE genotyping and a baseline MRI are required before starting. A severe ARIA event, brain hemorrhage, serious infusion reaction, or progression beyond early Alzheimer's disease usually ends treatment.
Can you switch to donanemab instead?
Donanemab (Kisunla) is another amyloid-clearing antibody, not a rescue drug for later dementia. The U.S. FDA states it was approved July 2, 2024 for mild cognitive impairment or mild dementia with confirmed amyloid pathology FDA approval snapshot.
That makes it a same-stage alternative, not a next step after progression to moderate or severe dementia. Switching also does not remove ARIA risk, because both drugs target amyloid. The decision depends on stage, amyloid status, APOE risk, prior tolerance, and infusion burden. If the person no longer has early Alzheimer's disease, the prescribing team will usually not start another amyloid antibody.
What care helps after lecanemab stops?
Standard dementia medicines may still help symptoms. According to the Alzheimer's Foundation of America, options include donepezil, rivastigmine, or galantamine for cognition, with memantine added for moderate-to-severe stages treatment guidance. Practical help often matters more than another prescription: Bring recent test scores, MRI results, APOE results, infusion dates, and a list of new symptoms to the next visit.
- review daily routine, sleep, exercise, hearing, vision, and mood
- simplify medications and check for drugs that worsen thinking
- plan home safety, driving, finances, wandering risk, and caregiver support
- discuss goals of care, legal papers, and future living needs
- ask the dementia team about clinical trials for the current stage





